VT Ablation in Ischemic Cardiomyopathy
Definition
Catheter ablation for ventricular tachycardia (VT) in patients with prior myocardial infarction involves electroanatomic substrate mapping of post-infarct scar and radiofrequency delivery to render VT noninducible. It is now supported as a first-line strategy in patients with clinically significant VT and ischemic cardiomyopathy who have not previously failed antiarrhythmic drugs.
Key Concepts
Mechanistic Basis
- Post-MI scar creates fixed anatomical barriers and slow conduction zones that support scar-based re-entrant VT (sustained monomorphic VT is the predominant form)
- Electroanatomic mapping defines the arrhythmic substrate; ablation targets sites of earliest activation (entrainment mapping), abnormal potentials (late potentials), and channels within scars
- Radiofrequency energy renders the substrate noninducible by eliminating slow conduction channels
Antiarrhythmic Drugs — Comparators and Limitations
- Sotalol (Class III + non-selective beta-blocker): preferred when LVEF ≥20%, eGFR ≥30 ml/min/1.73m², NYHA I/II, no torsades de pointes, no QT prolongation, and qualifying arrhythmia is not VT storm; dose 120 mg BD
- Amiodarone (Class III): preferred for severe ventricular dysfunction or electrical storm; dose 400 mg BD ×2w → 400 mg daily ×4w → 200 mg maintenance; more effective but higher noncardiac toxicity (pulmonary, thyroid, hepatic, neurological)
- Drug adverse events leading to discontinuation or dose reduction are common in long-term follow-up: 21.6% nonfatal in VANISH2 over 4.3 years (sources/vt-ablation-vanish2-nejm-2025, rating: very high)
VANISH2 Trial — First-Line Ablation vs AAD (2025)
- 416 patients, prior MI, clinically significant VT, all ICD recipients, no prior antiarrhythmic drug exposure for VT; 22 centres in Canada, USA, France; median follow-up 4.3 years (sources/vt-ablation-vanish2-nejm-2025, rating: very high)
- Primary endpoint (composite: death/VT storm/ICD shock/treated sustained VT >14 days): Ablation 50.7% vs drugs 60.6%; HR 0.75 (95% CI 0.58–0.97; P=0.03)
- Mortality alone: HR 0.84 (NS) — no mortality difference
- VT storm: HR 0.95 (NS) — no significant difference
- Appropriate ICD shock: HR 0.75 (NS trend)
- Treated sustained VT below ICD detection limit: HR 0.26 (95% CI 0.13–0.55) — the largest and most significant effect, driving primary endpoint difference
- Drug-related adverse events: 21.6% (nonfatal, leading to drug discontinuation/reduction) vs 3.4% in ablation arm; 1 death from pulmonary toxicity; 7 pulmonary infiltrates/fibrosis in drug arm
- Ablation procedural complications (30 days): Death 1.0%, stroke 1.0%, cardiac perforation 0.5%, vascular injury 2.5%
- Conclusion: First large RCT supporting catheter ablation as first-line therapy over AADs in ischemic VT; challenges conventional "drugs first, ablation after failure" paradigm
VANISH Trial — Ablation vs Escalated AAD (2016)
- Among patients with VT on baseline antiarrhythmic therapy, ablation + continuation of baseline drugs was superior to escalation of antiarrhythmic drug therapy for a composite of death, ICD shock, or VT storm (sources/VA-SCD-ESC-2022, rating: very high)
- Together, VANISH and VANISH2 support ablation over drug escalation at multiple stages: whether naive to drugs or already on them
Earlier Randomised Trials and the Guideline Evidence Base
| Trial | Population | Comparison | Key result |
|---|---|---|---|
| SMASH-VT (2007) | 128 post-MI patients with secondary-prevention ICD | Prophylactic substrate ablation vs medical therapy | Freedom from any appropriate ICD therapy 88% vs 67% (p=0.007); shocks 91% vs 69% (p=0.003); mortality 9% vs 17% (NS) |
| VTACH (2010) | 107 ischaemic patients with tolerated VT | Ablation before ICD vs ICD alone | Freedom from recurrent VA at 2 years 47% vs 29% (p=0.045); time to recurrence 18.6 vs 5.9 months; mortality 8.5% vs 8.6% |
| CALYPSO (2015) | Ischaemic ICD patients with prior appropriate therapy | Ablation vs AAD | Terminated after 27 patients; 41% of those failing screening were excluded because of prior AAD use |
| SMS (2017) | 111 ischaemic patients with unstable VT | Substrate ablation + ICD vs ICD alone | Event-free survival 49.0% vs 52.4% (NS); spontaneous VA episodes 2.8 vs 8.1 (p=0.015) |
- The 2019 consensus recommended ablation over drugs (Class I) for recurrent monomorphic VT in ischaemic heart disease despite chronic amiodarone, and conditionally for several other structural-heart-disease indications. The only recommendation supported by Level A evidence at that time was Class IIb for ablation after a first episode of monomorphic VT in ischaemic cardiomyopathy with an ICD; all other recommendations were Level B or C. (sources/vt-ablation-jaccep-2019, rating: high)
- Substrate targets include late potentials/LAVA, scar homogenisation, scar dechanneling and core isolation; non-inducibility remains the traditional endpoint but is imperfect and was not predictive in the non-ischaemic homogenisation study. (sources/vt-ablation-jaccep-2019, rating: high)
- Referral is often late: in a tertiary centre, 63% of structural-heart-disease referrals had ≥2 prior VT episodes separated by ≥1 month, and early referral was associated with a lower recurrence risk (HR 0.37, p=0.02). (sources/vt-ablation-jaccep-2019, rating: high)
- See concepts/VT-Ablation for the general mapping and technology overview.
Substrate Approach and Procedural Standards
- Ablation performed within 14 days of randomization in VANISH2
- Standardized approach: VT induction → electroanatomic mapping of the ventricular substrate → radiofrequency delivery to render VT noninducible
- 319 total ablation procedures were performed in VANISH2 (including 79 among drug-therapy patients who crossed over): underlines the complexity and repeated-procedure nature of VT management
- ICD programming was standardized to published guidelines in VANISH2
Residual Disease Burden Despite Treatment
- Even with the superior ablation strategy: 22.2% died, 21.7% had VT storm, 29.6% had ICD shock, 4.4% had treated sub-threshold VT over 4.3 years
- High residual burden demonstrates that VT in ischemic cardiomyopathy remains a severe condition with no curative option
Guideline Context
- Current AHA/ACC/HRS (2017) and ESC (2022) guidelines recommend antiarrhythmic drugs first with ablation for drug-refractory cases (Class I)
- VANISH2 directly challenges this sequence — first-line ablation now supported by the largest and longest RCT in this space
- Emergency catheter ablation for incessant VT/ES refractory to AADs: Class I in ESC 2022 (unchanged)
Contradictions / Open Questions
- Mortality benefit not established: VANISH2 was not powered to detect a mortality difference; both VANISH and VANISH2 show a trend toward lower mortality with ablation (HR ~0.84) but neither reached significance. A meta-analysis of ablation vs AAD trials might clarify this. (sources/vt-ablation-vanish2-nejm-2025)
- VT storm not reduced by ablation: Counter-intuitively, VANISH2 showed no significant reduction in VT storm with ablation (HR 0.95). This may reflect the acute re-entrant nature of storm in the immediate post-ablation period versus chronic suppression of sub-threshold VT. (sources/vt-ablation-vanish2-nejm-2025)
- Guideline lag: Current guidelines list catheter ablation only after drug failure; VANISH2 data are not yet incorporated into revised guidelines. The "drugs first" standard may change in next guideline iteration.
- Generalizability to non-ischemic VT: VANISH2 restricted to post-MI patients. Non-ischemic cardiomyopathy (DCM, ACM) has different substrate characteristics and ablation outcomes; this evidence cannot be directly extrapolated.
- Operator variability: Ablation outcomes depend heavily on operator/centre experience. VANISH2 was conducted at high-volume centres; real-world ablation outcomes at lower-volume centres may differ.
- Long-term amiodarone toxicity underestimated: Median 4.3-year follow-up may understate cumulative amiodarone toxicity risk (pulmonary, thyroid, neurologic); longer follow-up would likely further widen the safety gap. (sources/vt-ablation-vanish2-nejm-2025, sources/amiodarone-pulmonary-clin-chest-2004)
- The guideline evidence base was thin. Before VANISH2, the only Level A evidence for ablation in ischaemic VT was a Class IIb recommendation for a first episode of monomorphic VT; SMASH-VT, VTACH, VANISH and SMS were mostly Level B, and CALYPSO enrolled only 27 patients. VANISH2 now provides first-line randomised support but has not yet been incorporated into guidelines. (sources/vt-ablation-jaccep-2019, rating: high) (sources/vt-ablation-vanish2-nejm-2025, rating: very high)
Connections
- Part of concepts/VT-Ablation — the general ablation overview
- Related to concepts/Electrical-Storm — ablation is Class I for SMVT-related ES; VANISH2 supports use before drug failure
- Related to concepts/Amiodarone-Pulmonary-Toxicity — VANISH2 quantifies real-world pulmonary toxicity (1 death, 7 pulmonary infiltrates/fibrosis in AAD arm over 4.3 years)
- Related to concepts/Catheter-Ablation-AF — ablation technology and technique parallels
- Related to concepts/Late-Gadolinium-Enhancement — LGE-CMR delineates scar substrate targeted by VT ablation
- Related to concepts/Myocardial-Viability — ischemic cardiomyopathy substrate context
- Related to entities/Amiodarone — comparator drug; toxicity profile motivates ablation-first
- Related to concepts/Antiarrhythmic-Drugs — sotalol as comparator drug for lower-risk patients in VANISH2